Eisai Patent For Aricept For Severe Alzheimer's Disease Extends To 2013
This article was originally published in PharmAsia News
Japan's Supreme Court has rejected an appeal filed by generic drug makers, which effectively withheld a previous ruling to grant an extension to Eisai's Aricept (donepezil) for severe Alzheimer's disease until June 22, 2013
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.